CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the extension of its C-Scrub antimicrobial wash brand into the veterinary and animal health sector through the planned launch of a veterinary formulation of C-Scrub Wash 4%, marking the Company’s first entry into the animal health market. The Company intends to launch the veterinary formulation in the United Kingdom, where C-Scrub is already an established and commercially active human-use brand, with broader international expansion to follow. The global animal health market was estimated at approximately $68.7 billion in 2025 and is projected to reach $156.0 billion by 2033, growing at a compound annual growth rate of 11.0%, according to Grand...

Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead Highlights Significant Risk of Replacing Vaxart’s Highly Qualified Directors with Candidates Who Have No Relevant Expertise Urges Shareholders to Vote “FOR” ALL Six of Vaxart’s Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) — Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that it has filed its definitive proxy materials with the Securities and Exchange Commission in connection with its upcoming...

Hangzhou, June 01, 2026 (GLOBE NEWSWIRE) — Jiuzi Holdings, Inc. (Nasdaq: JZXN) (“Jiuzi” or the “Company”) today announced the latest developments regarding its AI intelligent imaging and data platform. The Company is preparing to advance the development of its next-generation AI intelligent imaging platform in accordance with its established strategic roadmap and is making systematic preparations for subsequent commercial deployment. The intelligent imaging platform is designed to enable enterprise customers to transition from traditional image monitoring and standalone data processing models to real-time intelligent analytics and data-driven decision-making. By integrating AI recognition capabilities, data processing architecture, and deployment systems, the Company is preparing to build a unified intelligent imaging and data...

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today presents the published abstract and poster from the ASCO Annual Meeting 2026. The abstract is shown below and the poster being presented today can be seen and downloaded at the bottom of the Phase III clinical trial tab on the Company’s website here.This is the second abstract and poster presented jointly with the Steering Committee of FLAMINGO-01 with statistically significant injection site reaction (ISR) immune response data, with subgroup analysis by the most prevalent HLA types. In the non-HLA-A*02...

Additional Notes represent full exercise of Initial Purchasers’ Option from previously announced Offering and closing of non-brokered private placement notes with Double Zero Capital Opportunistic capital raise with net proceeds expected to be used for the development of the Cariboo Gold Project and general corporate purposes A portion of net proceeds used to purchase cash-settled capped calls to offset potential economic dilution by effectively increasing the conversion premium to 100% (from 25%)MONTREAL, June 01, 2026 (GLOBE NEWSWIRE) — Osisko Development Corp. (NYSE: ODV, TSXV: ODV) (“Osisko Development” or the “Company“) announced today the closing on May 29, 2026 of an additional US$75.0 million aggregate principal amount of 4.125% convertible senior notes due 2031 (the “Notes“), consisting...

Alpha Cash Prepaid Mastercard joins Mastercard’s Public Transit Benefit program; benefit live June 1 CORNELIUS, N.C., June 01, 2026 (GLOBE NEWSWIRE) — Alpha Modus Holdings, Inc. (“Alpha Modus”) (NASDAQ: AMOD), through its subsidiary Alpha Modus Financial Services, LLC, announced today that holders of the Alpha Cash Prepaid Mastercard are now eligible for the Mastercard Public Transit Benefit, a program that returns $2.50 per month to cardholders who tap to ride public transit across 11 major metropolitan markets in the United States. The mechanics are straightforward: spend $10 or more via contactless payment at the point of transit entry in a participating city during a calendar month and receive a $2.50 statement credit automatically applied within 60 days. Eligible systems span MARTA in Atlanta, MBTA in Boston, CTA and...